Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 58, Issue 8, Pages 948-961Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2006.05.006
Keywords
tumour immunity; T regulatory cells
Categories
Funding
- Medical Research Council [G117/488] Funding Source: researchfish
- MRC [G117/488] Funding Source: UKRI
- Medical Research Council [G117/488] Funding Source: Medline
Ask authors/readers for more resources
Naturally occurring regulatory T cells (Tregs) have been shown to suppress immune responses to self-antigens, thereby limiting autoimmunity. In the case of tumours, where immune responses to self-antigens are beneficial and lead to elimination of the tumour, such suppressive activity is actually detrimental to the host. Manipulation of Tregs holds great promise for the immunotherapy of cancer. Several studies performed using rodent models and indicate that Tregs cells inhibit effective antitumour immune responses and that their removal promotes tumour rejection. The increasing number of studies of Tregs in patients with cancer also point to a role for these cells in promoting disease progression. This review summarises the findings of these studies and addresses the advantages and potential pitfalls of manipulating Treg activity for the treatment of cancer. (c) 2006 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available